Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134728) titled 'Alogliptin plus Low-Dose Pioglitazone for T2DM with MASLD' on Oct. 20.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shanghai Traditional Chinese Medicine Hospital
Condition:
Type 2 diabetes mellitus combined with metabolic disorder-related fatty liver disease
Intervention:
Control Group:Alogliptin tablets, 25 mg, to be taken orally once a day (QD).
Treatment duration: 12 weeks.
Intervention Group:Alogliptin tablets, 25 mg, to be taken orally once a day
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-11-01
Target Sample Size: Control Group:32;...